R

Radiopharm Theranostics Ltd
NASDAQ:RADX

Watchlist Manager
Radiopharm Theranostics Ltd
NASDAQ:RADX
Watchlist
Price: 4.97 USD 2.69% Market Closed
Market Cap: 11.6B USD

Intrinsic Value

RADX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RADX stock under the Base Case scenario is 39.55 USD. Compared to the current market price of 4.97 USD, Radiopharm Theranostics Ltd is Undervalued by 87%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RADX Intrinsic Value
39.55 USD
Undervaluation 87%
Intrinsic Value
Price
R
Base Case Scenario

Valuation History
Radiopharm Theranostics Ltd

Valuation History Unavailable

Historical valuation for RADX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare RADX to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about RAD?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Radiopharm Theranostics Ltd
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Radiopharm Theranostics Ltd

Balance Sheet Decomposition
Radiopharm Theranostics Ltd

Current Assets 44.4m
Cash & Short-Term Investments 36.4m
Receivables 6.3m
Other Current Assets 1.7m
Non-Current Assets 48.1m
Long-Term Investments 40k
PP&E 57.1k
Intangibles 48m
Efficiency

Free Cash Flow Analysis
Radiopharm Theranostics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Radiopharm Theranostics Ltd

Revenue
1.7m AUD
Cost of Revenue
-1.9m AUD
Gross Profit
-231.2k AUD
Operating Expenses
-37.5m AUD
Operating Income
-37.8m AUD
Other Expenses
-4.2m AUD
Net Income
-41.9m AUD
Fundamental Scores

RADX Profitability Score
Profitability Due Diligence

Radiopharm Theranostics Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative Gross Profit
Negative Operating Income
Negative Net Income
21/100
Profitability
Score

Radiopharm Theranostics Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

RADX Solvency Score
Solvency Due Diligence

Radiopharm Theranostics Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
55/100
Solvency
Score

Radiopharm Theranostics Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RADX Price Targets Summary
Radiopharm Theranostics Ltd

Wall Street analysts forecast RADX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RADX is 4.86 USD with a low forecast of 4.71 USD and a high forecast of 5.07 USD.

Lowest
Price Target
4.71 USD
5% Downside
Average
Price Target
4.86 USD
2% Downside
Highest
Price Target
5.07 USD
2% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Radiopharm Theranostics Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for RAD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

RAD Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one RADX stock?

The intrinsic value of one RADX stock under the Base Case scenario is 39.55 USD.

Is RADX stock undervalued or overvalued?

Compared to the current market price of 4.97 USD, Radiopharm Theranostics Ltd is Undervalued by 87%.

Back to Top